Country for PR: United States
Contributor: PR Newswire New York
Thursday, August 13 2020 - 22:06
Ajinomoto Bio-Pharma Services Expands Small Molecule Manufacturing Capabilities at its India Facility
WETTEREN, Belgium, Aug. 13, 2020 /PRNewswire-AsiaNet/ --

Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of 
biopharmaceutical contract development and manufacturing services, is pleased 
to announce a major expansion of small molecule manufacturing capabilities with 
the addition of a new production facility in Visakhapatnam, India. Construction 
of the 8,500 square meter facility began at the end of July 2020 and is 
expected to be completed mid-2022.

Logo -

To meet the current and future needs of customers, the new small molecule 
manufacturing facility doubles the production capacity at the site to 310 m(3) 
for active pharmaceutical ingredients (API) and intermediates and has dedicated 
equipment to manage OEB 4 high potency ingredients. Further, the site has 
completed renovations on existing laboratory space to support additional R&D 
activities. It is estimated that the expansion will create at least 60 new jobs 
at the site.

The US FDA approved Ajinomoto Bio-Pharma Services India manufacturing site, 
which was designed, constructed and is managed based on the Aji Bio-Pharma 
Belgian sites' GMP operating standards and quality systems, has successfully 
supported a number of the world's leading biopharmaceutical companies since its 
formation in 2011 and continues to win awards for sustainability and quality 

"We are very excited to be investing in this additional production capacity to 
continue delivering high quality, cost-effective small molecule manufacturing 
services for our customers," said K.V.V. Raju, Head of Site Operations and CEO, 
Ajinomoto Bio-Pharma India Pvt. Ltd. "This expansion exemplifies our commitment 
to our vision statement of being a leading, trusted, innovative partner to our 
clients and our people."

"The increased manufacturing capacity at Aji Bio-Pharma India offers a 
significant advantage for our small molecule customers, who now have a variety 
of options to meet their manufacturing needs," said Peter Stuyck, Sr. Vice 
President and Head of European Operations, Ajinomoto Bio-Pharma Services. "This 
expansion optimizes capacity across all locations and further enhances Aji 
Bio-Pharma's commitment in being a leading global and quality-driven CDMO with 
comprehensive service offerings."

About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated contract development and 
manufacturing organization with sites in Belgium, United States, Japan, and 
India, providing comprehensive development, cGMP manufacturing, and aseptic 
fill finish services for small and large molecule APIs and intermediates. 
Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and 
capabilities for pre-clinical and pilot programs to commercial quantities, 
including Corynex(R) protein expression technology, oligonucleotide synthesis, 
antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, 
continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is 
dedicated to providing a high level of quality and service to meet our client's 
needs. Learn more:

SOURCE: Ajinomoto Bio-Pharma Services